HKSE - Delayed Quote HKD

Zhaoke Ophthalmology Limited (6622.HK)

1.640
-0.020
(-1.20%)
At close: 4:08:14 PM GMT+8
Loading Chart for 6622.HK
  • Previous Close 1.660
  • Open 1.660
  • Bid 1.630 x --
  • Ask 1.640 x --
  • Day's Range 1.610 - 1.660
  • 52 Week Range 1.210 - 2.230
  • Volume 876,500
  • Avg. Volume 2,669,851
  • Market Cap (intraday) 895.668M
  • Beta (5Y Monthly) 1.00
  • PE Ratio (TTM) --
  • EPS (TTM) -0.450
  • Earnings Date Mar 24, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 2.46

Zhaoke Ophthalmology Limited, an ophthalmic pharmaceutical company, engages in the research, development, manufacture, and commercialization of therapies that address unmet medical needs in the People's Republic of China, South Korea, and Hong Kong. It is developing various drugs that cover ophthalmic indications, including dry eye diseases, wet age-related macular degeneration, diabetic macular edema, myopia, and glaucoma. The company was formerly known as China Ophthalmology Focus Limited. Zhaoke Ophthalmology Limited was incorporated in 2017 and is headquartered in Guangzhou, the People's Republic of China.

www.zkoph.com

294

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 6622.HK

View More

Performance Overview: 6622.HK

Trailing total returns as of 5/8/2025, which may include dividends or other distributions. Benchmark is HANG SENG INDEX (^HSI) .

YTD Return

6622.HK
35.54%
HANG SENG INDEX (^HSI)
13.54%

1-Year Return

6622.HK
8.61%
HANG SENG INDEX (^HSI)
24.36%

3-Year Return

6622.HK
60.39%
HANG SENG INDEX (^HSI)
13.87%

5-Year Return

6622.HK
89.43%
HANG SENG INDEX (^HSI)
6.00%

Compare To: 6622.HK

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 6622.HK

View More

Valuation Measures

Annual
As of 5/7/2025
  • Market Cap

    906.59M

  • Enterprise Value

    -108.59M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    12.27

  • Price/Book (mrq)

    0.45

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -8.02%

  • Return on Equity (ttm)

    -12.03%

  • Revenue (ttm)

    69.32M

  • Net Income Avi to Common (ttm)

    -237.49M

  • Diluted EPS (ttm)

    -0.450

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.19B

  • Total Debt/Equity (mrq)

    12.56%

  • Levered Free Cash Flow (ttm)

    -295.31M

Research Analysis: 6622.HK

View More

Company Insights: 6622.HK

Research Reports: 6622.HK

View More

People Also Watch